Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IqYmune Maintenance in CIDP (PRISM2)
NCT02317562Phase 3Terminated
- Sponsor
- LFB Group
- Start
- Nov 2015
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of IqYmune in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by LFB Group. Started Nov 2015; status: terminated.
02
Drugs
IqYmune
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT02317562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317562.